Overview
flowchart TD
companies_taigen_biotechnology["TaiGen Biotechnology"]
companies_taigen_biotechnology["Taiwan-based"]
companies_taigen_biotechnology -->|"related to"| companies_taigen_biotechnology
style companies_taigen_biotechnology fill:#81c784,stroke:#333,color:#000
companies_taigen_biotechnology["pharmaceutical"]
companies_taigen_biotechnology -->|"related to"| companies_taigen_biotechnology
style companies_taigen_biotechnology fill:#81c784,stroke:#333,color:#000
companies_taigen_biotechnology["company"]
companies_taigen_biotechnology -->|"related to"| companies_taigen_biotechnology
style companies_taigen_biotechnology fill:#81c784,stroke:#333,color:#000
companies_taigen_biotechnology["founded"]
companies_taigen_biotechnology -->|"related to"| companies_taigen_biotechnology
style companies_taigen_biotechnology fill:#81c784,stroke:#333,color:#000
style companies_taigen_biotechnology fill:#4fc3f7,stroke:#333,color:#000
TaiGen Biotechnology (太景生技) is a Taiwan-based pharmaceutical company founded in 2001 and headquartered in Taipei, Taiwan, focused on developing novel therapeutics for infectious diseases, central nervous system disorders, and oncology["@taigen2026"]. With a track record of successful drug development and a proprietary small molecule platform, TaiGen has established itself as a leading Taiwan-based pharmaceutical company with expanding global presence["@taiwan2026"].
Company Details
...Overview
Mermaid diagram (expand to render)
TaiGen Biotechnology (太景生技) is a Taiwan-based pharmaceutical company founded in 2001 and headquartered in Taipei, Taiwan, focused on developing novel therapeutics for infectious diseases, central nervous system disorders, and oncology["@taigen2026"]. With a track record of successful drug development and a proprietary small molecule platform, TaiGen has established itself as a leading Taiwan-based pharmaceutical company with expanding global presence["@taiwan2026"].
Company Details
| Attribute | Details |
|-----------|---------|
| Headquarters | Taipei, Taiwan |
| Founded | 2001 |
| Ticker | TPEX: 4157 |
| Focus Areas | Infectious diseases, CNS disorders, oncology |
| Approach | Small molecule drug development, proprietary chemistry platform |
| Website | taigenbiotech.com |
Small Molecule Drug Development
TaiGen's drug discovery platform leverages proprietary medicinal chemistry capabilities[@wermuth2016]:
- Novel chemical entity discovery: Identification of new chemical skeletons with favorable drug-like properties
- Lead optimization: Systematic structure-activity relationship (SAR) studies
- Preclinical development: IND-enabling studies for clinical candidates
- Clinical development: Phase 1-3 clinical trial capabilities
The company's platform emphasizes:
Blood-brain barrier penetration: Essential for CNS therapeutics
Oral bioavailability: Patient-friendly chronic dosing
Metabolic stability: Reduced pill burden
Safety optimization: Early safety assessmentKey Capabilities
| Capability | Description |
|------------|-------------|
| Medicinal Chemistry | Proprietary compound libraries and synthesis |
| In vitro Pharmacology | Target engagement and selectivity profiling |
| In vivo Pharmacology | rodent models of disease |
| ADMET | Absorption, metabolism, pharmacokinetics |
Parkinson's Disease Program
CNS Focus
TaiGen has been expanding into neurological disorders, recognizing the significant unmet medical need in Parkinson's disease[@kalia2015]:
Program Rationale:
- Over 10 million patients worldwide lack disease-modifying therapies
- Growing understanding of PD pathophysiology enables targeted drug discovery
- Small molecules offer advantages for chronic disease management
Therapeutic Targets
TaiGen's PD program focuses on several pathological pathways[@poewe2017]:
| Target | Mechanism | Development Stage |
|--------|-----------|-------------------|
| Neuroprotection | Dopaminergic neuron survival | Research |
| Neuroinflammation | Microglial activation | Research |
| Mitochondrial function | Complex I protection | Research |
| Alpha-synuclein | Aggregation inhibition | Research |
Development Strategy
The company's approach includes:
Target validation: Robust preclinical proof-of-concept
Lead identification: High-throughput screening and fragment-based design
Clinical candidate selection: Optimized potency, PK, and safety
Clinical development: Strategic trial design for PDOther Pipeline Programs
Antibiotics
TaiGen has a strong track record in antibiotic development[@silver2018]:
- TG-001: Novel antibiotic targeting resistant bacteria
- Mechanism: Novel target compared to existing classes
- Status: Phase 2 clinical trials
Oncology
The company's oncology portfolio includes[@targeted2019]:
- Targeted therapies for solid tumors
- Combination approaches with standard of care
- Biomarker-driven patient selection
Inflammatory Diseases
- Immunomodulatory approaches
- Novel anti-inflammatory mechanisms
Research Collaborations
TaiGen maintains active collaborations with research institutions and pharmaceutical partners[@national2026]:
Academic Partnerships
- National Taiwan University (NTU): Drug discovery and clinical translation
- Academia Sinica: Basic research in neuroscience
- National Yang Ming Chiao Tung University: Pharmacology and toxicology
- Taipei Medical University: Clinical research infrastructure
Industry Partnerships
- Licensing and co-development deals with international pharma
- Contract research organization relationships
- Manufacturing partnerships
Clinical Development Capabilities
TaiGen has established clinical development infrastructure:
- Phase 1-2 clinical trial capabilities in Taiwan
- Access to Asian clinical trial networks
- Regulatory expertise in TFDA, PMDA, FDA submissions
Market Opportunity
Parkinson's Disease Market
The global PD market represents significant opportunity[@dorsey2023]:
- Prevalence increasing with aging populations
- Limited disease-modifying therapies available
- High unmet need for neuroprotective agents
- Growing investment from pharmaceutical companies
Taiwan Strategic Advantages
Taiwan offers unique advantages for drug development:
- Cost-effective R&D operations compared to US/EU
- Strong academic research in neuroscience
- Strategic location for Asian clinical trials
- Government incentives for biotechnology
Regulatory Strategy
TaiGen is developing regulatory pathways in:
- Taiwan FDA (TFDA)
- Japan PMDA
- US FDA
- EU EMA
Competitive Landscape
TaiGen competes with companies in the antibiotic and CNS spaces:
| Company | Focus | Examples |
|---------|-------|----------|
| Merck | Antibiotics, CNS | Antibiotic pipeline |
| GSK | Antibiotics | New antibiotic development |
| Pfizer | CNS | Parkinson's programs |
| TaiGen | Antibiotics, CNS | TG-001, PD program |
Investment and Funding
TaiGen has been funded through:
- Taiwan venture capital
- Government grants (MOEA, NSTC)
- Strategic partnerships
- Public listing (TPEX)
Future Directions
TaiGen's development strategy includes[@dimasi2023]:
Advancing PD program toward clinical candidates
Expanding CNS portfolio beyond infectious diseases
Establishing additional global partnerships
Pursuing regulatory approvals across key markets
- [Parkinson's Disease](/genes/ar)
- [Small Molecule Therapeutics](/genes/th)
- CNS Drug Development
- [Taiwanese Biotechnology Companies in Parkinson's Disease](/genes/ar)
- [Neuroprotection](/therapeutics/neuroprotection)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
TaiGen Biotechnology, Company Website (2026)
Taiwan Biotechnology Industry Association, Taiwan Biotech Companies Directory (2026)
[Wermuth CG, The practice of medicinal chemistry (2016)](https://pubmed.ncbi.nlm.nih.gov/27592467/)
[Kalia LV, et al, Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25904081/)
[Poewe W, et al, Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28240536/)
[Silver LL, Novel antibiotics for resistant infections (2018)](https://pubmed.ncbi.nlm.nih.gov/29753265/)
[Unknown, Targeted Oncology. Cancer therapeutics development (2019)](https://pubmed.ncbi.nlm.nih.gov/31019278/)
National Taiwan University, Research Collaboration Programs (2026)
[Dorsey ER, et al, Global, regional, and national burden of Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37771385/)
[DiMasi JA, et al, Trends in R&D investment in the pharmaceutical industry (2023)](https://pubmed.ncbi.nlm.nih.gov/36922493/)